Retatrutide: triple GIP/GLP-1/glucagon receptor agonist research overview

Retatrutide (LY3437943) is a synthetic triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, developed by Eli Lilly and Company. As the first molecule in the GLP-1/GIP/glucagon triple-agonist class to complete phase 2 trials, retatrutide has attracted substantial scientific attention for the magnitude of weight reduction reported in its 48-week phase 2 obesity trial, which exceeded the effect sizes observed with approved GLP-1 and dual GIP/GLP-1 agents at the time of publication. Phase 3 trials (the TRIUMPH program) are ongoing as of 2026. The compound is not yet approved by the FDA or any major regulatory agency.

What is retatrutide?

Retatrutide is a synthetic polypeptide with a molecular weight of 4,731.33 Da, developed by Eli Lilly under the designation LY3437943. Like tirzepatide (LY3298176), its peptide backbone draws from the GIP hormone family, but retatrutide extends the dual GIP/GLP-1 pharmacology of tirzepatide by incorporating agonist activity at the glucagon receptor (GCGR) as well. This triple receptor engagement is the defining feature that distinguishes retatrutide from all currently approved incretin-based agents. The compound employs a fatty diacid acylation via a linker for albumin binding, extending its plasma half-life to approximately 6 days and enabling once-weekly subcutaneous administration.

Retatrutide has not received regulatory approval from the FDA, EMA, or any other major regulatory body as of May 2026. It has completed a phase 2 dose-ranging obesity trial (NCT04881760) and a phase 2 type 2 diabetes trial (NCT05275959), and the phase 3 TRIUMPH program for obesity and related comorbidities is ongoing (NCT05931367). In research contexts, retatrutide is classified as an investigational compound available through research-use vendors; it is not approved for self-administration.

Mechanism of action

Retatrutide simultaneously activates three class B G protein-coupled receptors: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). GLP-1R and GIPR activation drives glucose-dependent insulin secretion, glucagon suppression in hyperglycemic states, and appetite suppression via central hypothalamic and brainstem circuits — mechanisms shared with semaglutide and tirzepatide. The critical additional dimension is GCGR agonism. Glucagon receptor activation in the liver stimulates hepatic glucose production, which might seem counterproductive, but at the level of energy metabolism, GCGR agonism significantly increases energy expenditure, promotes lipolysis, and has been shown in preclinical and phase 1 studies to reduce hepatic fat content and improve hepatic insulin sensitivity.

The theoretical challenge of combining GCGR agonism — which raises blood glucose — with GLP-1R and GIPR agonism — which lower blood glucose — is resolved by engineering the relative receptor affinities to achieve net glycemic neutrality or improvement. In retatrutide's published phase 2 data, the 8 mg and 12 mg doses achieved reductions in HbA1c in type 2 diabetes participants while producing energy expenditure increases that contributed to weight loss significantly greater than that seen with GLP-1 alone. The glucagon component is hypothesized to drive enhanced thermogenesis in brown and beige adipose tissue and accelerated hepatic fat oxidation, effects that complement the appetite suppression mediated by GLP-1R and the additional insulinotropic and adipose-regulatory effects of GIPR activation (see citations).

In the phase 2 MASLD trial (NCT05519579), retatrutide produced a mean 82% reduction in liver fat content as measured by MRI-PDFF at 24 weeks in participants with metabolic dysfunction-associated steatotic liver disease. This finding aligns with the hypothesized contribution of glucagon receptor-mediated hepatic fat clearance and positions retatrutide as a potentially important research tool for understanding MASLD biology independently of its weight effects (see citations).

What the research shows

The pivotal phase 2 obesity trial (NCT04881760), published by Jastreboff et al. in the New England Journal of Medicine in 2023 (PMID 37366315), enrolled 338 adults with obesity or overweight without type 2 diabetes and evaluated retatrutide at 1, 4, 8, or 12 mg weekly subcutaneously over 48 weeks versus placebo. At 48 weeks, mean weight reduction was −2.1% in the placebo group, versus −17.1% in the 8 mg group and −24.2% in the 12 mg group (see citations). The 12 mg dose produced weight reductions exceeding 20% in a substantial fraction of participants — effect sizes that had not previously been reported for any single-agent injectable at the time of publication.

The phase 2 type 2 diabetes trial, published by Rosenstock et al. in The Lancet in 2023 (PMID 37385280), enrolled 281 adults with type 2 diabetes inadequately controlled on metformin with or without SGLT-2 inhibitors, comparing retatrutide 4, 8, and 12 mg weekly to placebo and dulaglutide 1.5 mg. At 36 weeks, the 12 mg dose produced a mean HbA1c reduction of 2.2% from baseline versus 0.2% with placebo, with 82% of participants achieving HbA1c ≤6.5%. Body weight was reduced by a mean of 16.9% in the 12 mg group (see citations). These glycemic and weight outcomes exceeded comparator results with dulaglutide 1.5 mg.

The phase 2a MASLD trial (NCT05519579), published in Nature Medicine in 2024 (PMID 38858523), enrolled adults with MASLD and obesity. Retatrutide produced a mean 82.4% relative reduction in liver fat at 24 weeks for the 12 mg dose versus 3.8% with placebo, a finding with significant implications for MASLD research. The ongoing TRIUMPH phase 3 program (NCT05931367 and related trials) is evaluating retatrutide across obesity, type 2 diabetes, obstructive sleep apnea, and osteoarthritis endpoints, with results anticipated through 2026–2028.

Pharmacokinetics

Retatrutide has a plasma half-life of approximately 6 days, enabling once-weekly subcutaneous dosing and achievement of steady-state concentrations after 4–5 weeks of weekly administration. Like tirzepatide, the extended half-life is achieved via a fatty diacid side chain enabling reversible albumin binding, reducing renal filtration and slowing receptor-mediated clearance. Pharmacokinetic data from the phase 1b dose-escalation study in type 2 diabetes (Urva et al., The Lancet, 2022; PMID 36354040) confirmed dose-proportional exposure and a half-life consistent with once-weekly dosing across the evaluated dose range (see citations).

Following subcutaneous injection, peak plasma concentrations are achieved within 8–72 hours (consistent with the GIP/GLP-1 agonist class). Retatrutide is metabolized via proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid linker; it is not a CYP450 substrate. The published phase 2 obesity trial (PMID 37366315) employed a dose-escalation scheme of 4 to 8 to 12 weeks per dose step to manage gastrointestinal tolerability. Full pharmacokinetic parameter tables are available in the published phase 1b paper and will be provided with full prescribing information if and when regulatory approval is granted.

Common research dose ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

The phase 2 obesity trial (Jastreboff et al., PMID 37366315) evaluated once-weekly subcutaneous doses of 1, 4, 8, and 12 mg following dose escalation. The phase 2 type 2 diabetes trial (Rosenstock et al., PMID 37385280) evaluated 4, 8, and 12 mg weekly. Literature reports once-weekly subcutaneous dosing; the phase 2 trial evaluated maintenance doses of 1, 4, 8, and 12 mg following dose escalation from lower starting levels. The ClinicalTrials.gov registry for NCT04881760 documents the full escalation regimen used in the obesity trial (see citations).

Because retatrutide has not received regulatory approval, there is no FDA-approved prescribing information to reference for clinical dose guidance. All dose ranges in the literature derive from investigational clinical trial protocols. Researchers should consult the published trial protocols and ClinicalTrials.gov registry entries, and note that experimental use outside an approved clinical study requires appropriate institutional and regulatory oversight.

Storage and handling

Lyophilized retatrutide is stored at −20 °C in a sealed, desiccant-protected vial. Once reconstituted, solutions should be maintained at 2–8 °C and used within 28 days. Reconstituted solutions should not be frozen; repeated freeze-thaw cycling, prolonged ambient temperature exposure, and direct light should all be avoided. These storage parameters are consistent with the broader class of fatty-acid-acylated polypeptide research compounds, including semaglutide and tirzepatide. Because retatrutide does not yet have an FDA-approved prescribing information document, storage guidance for research-grade material is based on the general stability characteristics of structurally analogous acylated peptides and vendor certificate-of-analysis documentation.

What retatrutide is NOT

Retatrutide is frequently discussed alongside semaglutide and tirzepatide as if these compounds are interchangeable; they are not. Retatrutide is not tirzepatide: tirzepatide is a dual GIP/GLP-1 agonist with no meaningful glucagon receptor activity, a 39-amino acid GIP-derived backbone, and FDA approval for two indications. Retatrutide adds a third pharmacological action at the glucagon receptor to tirzepatide's dual incretin profile, making it meaningfully more complex in mechanism and not yet approved. Retatrutide is not semaglutide, which is a GLP-1 monoagonist with a structurally distinct 31-amino acid backbone. Retatrutide is not survodutide or mazdutide, which are GLP-1/glucagon dual agonists lacking the GIP receptor component. Researchers sourcing retatrutide for investigational use should verify molecular weight (4,731.33 Da), receptor pharmacology documentation, and COA data from their supplier, as vendor naming of triple-agonist compounds varies significantly in the research market.

References

The citations below cover the primary sources underlying the claims in this article. Primary data sources include the phase 2 obesity trial (Jastreboff et al., N Engl J Med, 2023, PMID 37366315), the phase 2 type 2 diabetes trial (Rosenstock et al., The Lancet, 2023, PMID 37385280), the phase 2a MASLD trial (Nature Medicine, 2024, PMID 38858523), the phase 1b dose-escalation pharmacokinetics study (Urva et al., The Lancet, 2022, PMID 36354040), and the ClinicalTrials.gov registry entry for NCT04881760. The TRIUMPH phase 3 program (NCT05931367) is ongoing.